Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4632.2008.03621.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis.
Am J Trop Med Hyg
April 2024
Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, India.
Post-kala-azar dermal leishmaniasis (PKDL), the dermal sequel to visceral leishmaniasis (VL), is characterized by hypopigmented macules (macular) and/or papules and nodules (polymorphic). Post-kala-azar dermal leishmaniasis plays a significant role in disease transmission, emphasizing the need for monitoring chemotherapeutic effectiveness. Accordingly, this study aimed to quantify the parasite burden in PKDL patients after treatment with miltefosine by a quantitative polymerase chain reaction (qPCR).
View Article and Find Full Text PDFCase Report: An Atypical Case of Post-Kala-Azar Dermal Leishmaniasis with Ulcers and Verrucous Lesions: Clinical and Therapeutic Implications.
Am J Trop Med Hyg
January 2024
Stanley Browne Laboratory, The Leprosy Mission Community Hospital, Nand Nagari, New Delhi, India.
About 75% cases of post-kala-azar dermal leishmaniasis (PKDL) occur in India. Although the classic description of PKDL is the progression from initial hypopigmented macular lesions to papules to plaques and nodular lesions, atypical morphologies are also seen and are easily missed or misdiagnosed. We report a case of a 27-year-old man who presented to us with multiple acral ulcers and verrucous lesions for 5 years.
View Article and Find Full Text PDFDoes immune dysregulation contribute towards development of hypopigmentation in Indian post kala-azar dermal leishmaniasis?
Exp Dermatol
June 2023
Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Post kala-azar dermal leishmaniasis (PKDL), a sequel of apparently cured visceral leishmaniasis (VL) presents with papulonodular (polymorphic) or hypopigmented lesions (macular) and is the proposed disease reservoir. As hypopigmentation appears consistently in PKDL, especially the macular form, this study aimed to delineate immune factors that singly or in combination could contribute towards this hypopigmentation. At lesional sites, the presence of melanocytes and CD8 T-cells was assessed by immunohistochemistry and mRNA expression of melanogenic markers (tyrosinase, tyrosinase-related protein-1 and MITF) by droplet digital PCR, while plasma levels of cytokines and chemokines were measured by a multiplex assay.
View Article and Find Full Text PDFPost Kala-Azar Dermal Leishmaniasis: Clinical Features and Differential Diagnosis.
Indian J Dermatol
January 2021
Department of Dermatology, Bankura Sammilani Medical College, Bankura, West Bengal, India.
Article Synopsis
- * The disease presents with skin lesions, which can vary widely, including hypopigmented patches and nodular lesions, and can even have atypical forms like photosensitivity or ulcerative wounds.
- * Early recognition and treatment of PKDL are crucial for preventing disease spread, as the disease itself causes minimal initial harm but can serve as a reservoir for transmission in the community.
Mixed Cutaneous Infection Caused by Leishmania and Dermatophytes: A Rare Coincidence or Immunological Fact.
Case Rep Dermatol Med
March 2021
Department of Biochemistry, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh 273013, India.
Leishmaniasis was first described in 1824, in the Jessore district of Bengal (now Bangladesh) and more prevalent in Bihar, Uttar Pradesh, Jharkhand, and West Bengal. The disease is associated with depressed cellular immunity. Tinea is a fungal infection of the skin, which can become more extensively pathogenic particularly in patients with depressed cell-mediated immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!